Personal communication: Trial NCT00148460 by Boehringer Ingelheim

[AI-generated summary based on information about this trial as reported in the review; it may contain errors.] Based on the personal communication, the trial NCT00148460 was conducted in 2005 with a sample size of 267 participants. It was a randomized controlled trials assessing fibrinolytic agents exclusively in Asian patients (evaluating trials across three Asian countries). The study enrolled adult participants aged 18–75 years presenting with ST-segment elevation myocardial infarction (STEMI) within 6 hours of symptom onset, and aspirin use was part of the treatment protocol. The trial compared two treatment groups: tenecteplase plus parenteral anticoagulants (n=130) versus accelerated infusion alteplase plus parenteral anticoagulants (n=137). Regarding angiographic outcomes, the study reported a TIMI 3 flow rate (complete perfusion) of 60.1% at 60–90 minutes after administering thrombolytics.